Before PSM, individuals with GLP-1 RA prescriptions were younger; female; identified as not Hispanic or Latino or White; had higher rates of hypertension, dyslipidemia, and ischemic heart disease; and greater use of insulin, metformin, glipizide, sodium-glucose cotransporter 2 inhibitors, and renin-angiotensin-aldosterone system inhibitors compared with individuals without GLP-1 RA prescriptions. The gene discussed is INS; the disease is metabolic syndrome.